Cited by 817Colorectal Cancer Screening and DetectionGlobal Cancer Incidence and ScreeningColorectal Cancer Surgical Treatments

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death

Open access
Bretthauer, Michael, Løberg, Magnus, Wieszczy, Paulina, Kalager, Mette, Emilsson, Louise, Garborg, Kjetil, Rupinski, Maciej, Dekker, Evelien +13 more·2022·New England Journal of Medicine

Abstract

BACKGROUND: Although colonoscopy is widely used as a screening test to detect colorectal cancer, its effect on the risks of colorectal cancer and related death is unclear. METHODS: We performed a pragmatic, randomized trial involving presumptively healthy men and women 55 to 64 years of age drawn from population registries in Poland, Norway, Sweden, and the Netherlands between 2009 and 2014. The participants were randomly assigned in a 1:2 ratio either to receive an invitation to undergo a single screening colonoscopy (the invited group) or to receive no invitation or screening (the usual-care group). The primary end points were the risks of colorectal cancer and related death, and the secondary end point was death from any cause. RESULTS: Follow-up data were available for 84,585 participants in Poland, Norway, and Sweden - 28,220 in the invited group, 11,843 of whom (42.0%) underwent screening, and 56,365 in the usual-care group. A total of 15 participants had major bleeding after polyp removal. No perforations or screening-related deaths occurred within 30 days after colonoscopy. During a median follow-up of 10 years, 259 cases of colorectal cancer were diagnosed in the invited group as compared with 622 cases in the usual-care group. In intention-to-screen analyses, the risk of colorectal cancer at 10 years was 0.98% in the invited group and 1.20% in the usual-care group, a risk reduction of 18% (risk ratio, 0.82; 95% confidence interval [CI], 0.70 to 0.93). The risk of death from colorectal cancer was 0.28% in the invited group and 0.31% in the usual-care group (risk ratio, 0.90; 95% CI, 0.64 to 1.16). The number needed to invite to undergo screening to prevent one case of colorectal cancer was 455 (95% CI, 270 to 1429). The risk of death from any cause was 11.03% in the invited group and 11.04% in the usual-care group (risk ratio, 0.99; 95% CI, 0.96 to 1.04). CONCLUSIONS: In this randomized trial, the risk of colorectal cancer at 10 years was lower among participants who were invited to undergo screening colonoscopy than among those who were assigned to no screening. (Funded by the Research Council of Norway and others; NordICC ClinicalTrials.gov number, NCT00883792.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2208375

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A four-country study in northern Europe with 5-year colorectal cancer screening in 84585 patients using colonoscopy demonstrated a similar result.

    “A similar result was demonstrated in a four-country study in northern Europe with 5-year CRC screening in 84585 patients using colonoscopy[67].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bretthauer, M., Løberg, M., Wieszczy, P., Kalager, M., Emilsson, L., Garborg, K., Rupinski, M., Dekker, E., Spaander, M., Bugajski, M., Holme, Ø., Zauber, A. G., Pilonis, N. D., Mroz, A., Kuipers, E. J., Shi, J., Hernán, M. A., Adami, H.-O., Regula, J., Hoff, G., & Kaminski, M. F.
Affiliations
  • Oslo University Hospital (NO)
  • From the Clinical Effectiveness Research Group (M. Bretthauer, M.L., P.W., M.K., K.G., M. Bugajski, Ø.H., H.-O.A., M.F.K.) and the Department of General Practice, Institute of Health and Society (L.E.), University of Oslo, the Clinical Effectiveness Research Group, Department of Transplantation Medicine, Oslo University Hospital (M. Bretthauer, M.L., M.K., K.G., Ø.H., H.-O.A.), and the Cancer Registry of Norway (G.H.), Oslo, the Institute of Clinical Medicine, University of Tromsø, Tromsø (M. Bretthauer), and the Department of Research and Development, Telemark Hospital, Skien (G.H.) — all in Norway; the Department of Gastroenterological Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (P.W., M.R., M. Bugajski, N.D.P., A.M., J.R., M.F.K.), and the Departments of Pathology (A.M.) and Gastroenterological Oncology (P.W., M.R., M. Bugajski, N.D.P., A.M., J.R., M.F.K.), Medical Center of Postgraduate Education — both in Warsaw, Poland; Vårdcentralen Värmlands Nysäter and the Cen...
Venue
New England Journal of Medicine
Published
2022-10-27
Volume
387
Issue
17
Pages
1547-1556
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4303940405
Cited by
817
References
3
Citations by year
2026: 158 · 2025: 227 · 2024: 240 · 2023: 181 · 2022: 10 · 2012: 1
FWCI
68.74
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
  • Duo Research Archive (University of Oslo) (submittedVersion)
Funders
  • the Netherlands Organisation for Health Research and Development of the Dutch Ministry of Health (ZonMW 120720012)
  • Swedish Cancer Foundation (grant no. 2010/345 and CAN 2013/553)
  • National Centre for Research and Development of Poland (grant no. N R13 0024 04)
  • Polish-Norwegian Research Programme (Pol-Nor/204233/30/2013)
  • Medical Center for Postgraduate Education (501-1-09-12-12/22)
  • AFA Sweden (grant no. 130072)
  • Centre for Translational Molecular Medicine the Netherlands (CTMM DeCoDe)
  • Research Council of Norway (grant no. 197309)
  • Health Fund of South-East Norway (grant no. 5135)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
colorectal cancer screening, colonoscopy, colorectal cancer incidence, colorectal cancer mortality, screening invitations, colorectal polyps
MeSH terms
Colonic Polyps, Colonoscopy, Europe, Female, Follow-Up Studies, Humans, Male, Mass Screening, Middle Aged, Risk, Colorectal Neoplasms, Odds Ratio, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review